Compare Repligen Corporation Common Stock (RGEN) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.09 (market cap $4.39B). The key difference: Repligen Corporation Common Stock is far larger — about 2.5× State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 42 Days on average.
| RGEN | SJNK | |
|---|---|---|
Market Cap | $11.14B | $4.39B |
Volume | 1,259,263 | 1,736,904 |
Sector | Health | Fixed Income |
52-Week High | $194.57 | $25.57 |
52-Week Low | $102.87 | $24.10 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SJNK trades at $24.19, showing minimal daily movement with a slight decline of 0.21%. The technical outlook appears bearish based on moving averages, though oscillators suggest neutral conditions. Recent corporate actions include consistent dividend payments, with three distributions scheduled for late 2026 ranging from $0.14 to $0.15 per share. Institutional activity shows mixed sentiment with both position reductions and maintained stakes among major holders.
The ETF faces headwinds from bearish technical indicators while maintaining dividend distributions. Key risks include interest rate sensitivity and institutional selling pressure. The neutral oscillator reading suggests potential for stabilization, but the overall technical picture warrants caution for near-term positioning in this high-yield bond ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
